MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its earnings results on Monday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.07), FiscalAI reports.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX opened at $18.84 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -5.35 and a beta of 1.01. The company’s 50-day moving average is $17.47 and its two-hundred day moving average is $15.31. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

Insider Activity at MoonLake Immunotherapeutics

In other news, CEO Da Silva Jorge Santos sold 98,127 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $18.41, for a total value of $1,806,518.07. Following the transaction, the chief executive officer directly owned 2,976,766 shares in the company, valued at approximately $54,802,262.06. This represents a 3.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the sale, the director directly owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. The trade was a 78.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,900,000 shares of company stock worth $65,714,663. Company insiders own 12.05% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Hsbc Holdings PLC acquired a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $147,000. Virtu Financial LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth $166,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at about $47,000. Vident Advisory LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at about $204,000. Finally, Virtus Investment Advisers LLC increased its holdings in shares of MoonLake Immunotherapeutics by 595.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock valued at $237,000 after purchasing an additional 15,402 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

Key Headlines Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: MoonLake said its final pre-BLA meeting with the FDA went well, with alignment on submission plans for SLK, reducing regulatory uncertainty and boosting confidence in a potential approval path. Article Title
• Positive Sentiment: BTIG reiterated a Buy rating and maintained a $30 price target, citing a de-risked path to the 2026 BLA and strong SLK data. Article Title
• Positive Sentiment: HC Wainwright raised its price target to $45 from $40 and kept a Buy rating, reflecting higher optimism around commercial potential. Article Title
• Positive Sentiment: TD Cowen reiterated a Buy rating, saying sonelokimab could reach a 2027 launch and potentially generate more than $3 billion in peak sales. Article Title
• Positive Sentiment: Multiple reports said the FDA meeting helped MoonLake clear a key regulatory hurdle, which traders interpreted as a meaningful step toward filing and eventual approval. Article Title
• Neutral Sentiment: The company’s quarterly earnings were still negative and missed estimates, but the loss appears secondary to the regulatory and pipeline news. Article Title

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, March 30th. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $12.00 to $40.00 in a research note on Thursday, March 19th. Royal Bank Of Canada boosted their target price on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $24.00 in a research note on Monday, March 23rd. Finally, HC Wainwright boosted their target price on shares of MoonLake Immunotherapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus target price of $23.85.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.